Shots:

• Novartis to receive $20M (€17.9M) up front- regulatory and commercial milestones plus royalties on sales. Pharming to get exclusive rights to develop and commercialize Novartis’ CDZ173 (leniolisib). Additionally- Pharming will work with Novartis for enrolling patients in ongoing trials  
• Novartis has accomplished all the preclinical and clinical activities regarding product and will continue to run ongoing registration-enabling trial plus ongoing open label extension study. Post approval of product- Pharming is eligible to commercialize the product in the US and Europe  
• CDZ173 is a delta isoform of the 110 kDa catalytic subunit of class IA PI3K involved in inhibiting the production of phosphatidylinositol-3-4-5-trisphosphate (PIP3) and is currently evaluated in registration-enabling P-II/III trial. Additionally- it has shown well tolerated & safe results in P-I for APDS patients

Click here to­ read full press release/ article | Ref: Pharming | Image: Industry Hearald24